Deleted Tweets From Scott Gottlieb, R-D.C.
Scott Gottlieb's accounts: SteveFDA
Tracked Between: October 20, 2017-January 20, 2021
SteveFDA (R-D.C.)
@SGottliebFDA
RT @WHO: We are seeing a dramatic increase in #measles infections in the European Region. 2018: 41,000 (Jan-Jun) 2017: 23,9… https://t.co/edBIOTh0YR
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDAJobs: We were thrilled to host students from the George Washington University Summer Institute today on the White Oak Cam… https://t.co/7hYAmBefgT
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDAOncology: "Our regulatory work needs to remain as advanced as the many new cancer therapies currently working their way throu… https://t.co/jOEb1IJZPl
SteveFDA (R-D.C.)
@SGottliebFDA
RT @NIHDirector: With recent gene therapy breakthroughs, #NIH & @US_FDA are working together to ensure federal oversight framework k… https://t.co/pYPYZTurYT
SteveFDA (R-D.C.)
@SGottliebFDA
3/3 We’re optimistic this work will result in new, data-driven guidelines from medical professional societies that can be easily accessible to prescribers to decrease unnecessary/inappropriate exposure to opioids while ensuring appropriate treatment for patients with medical need
SteveFDA (R-D.C.)
@SGottliebFDA
THREAD: 1/3 #FDA today announced new steps we’re taking to advance the development of evidence-based, indication-specific guidelines to help guide more appropriate prescribing of opioid analgesics: https://t.co/GckBxOiiuI
SteveFDA (R-D.C.)
@SGottliebFDA
2/3 Work under contract with the National Academies of Sciences, Engineering, and Medicine can assist in creating evidence-based guidelines to treat acute pain resulting from specific medical conditions and common surgical procedures for which these opioids are prescribed.
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDATobacco: A new tobacco compliance video from FDA is available with important info for tobacco importers including: tariff cl… https://t.co/w1wHyRfmm3
SteveFDA (R-D.C.)
@SGottliebFDA
RT @SGottliebFDA: THREAD: 1/3 #FDA today announced new steps we’re taking to advance the development of evidence-based, indication-sp… https://t.co/fJcM7lUXC8
SteveFDA (R-D.C.)
@SGottliebFDA
RT @endpts: #Osteoarthritis: #FDA drafts guidance on developing drugs, devices, biologics https://t.co/woWNB26LTM by @ZacharyBrennan via @RAPSorg
SteveFDA (R-D.C.)
@SGottliebFDA
RT @AACR: On Sept. 6th, @FDAOncology and the AACR are holding a workshop to discuss the development of non-clinical models th… https://t.co/AYBokPi3Dl
SteveFDA (R-D.C.)
@SGottliebFDA
RT @RAPSorg: #Osteoarthritis: @US_FDA Drafts Guidance on Developing Drugs, Devices, Biologics | #Regulatory Focus… https://t.co/iCss2bOI0C
SteveFDA (R-D.C.)
@SGottliebFDA
FDA is actively working to help the people of Hawaii and assess potential impacts to FDA-regulated industry. We know the importance of the agriculture and food sectors to the islands and we are committed to working with the state to help minimize any impacts from #HurricaneLane.
SteveFDA (R-D.C.)
@SGottliebFDA
We are monitoring #HurricaneLane closely. In coordination with federal partners, we stand ready to assist Hawaii. https://t.co/5TU23BmHto
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDATobacco: This summer marks one year since Commissioner @SGottliebFDA announced FDA’s Comprehensive Plan for Tobacco and Nico… https://t.co/Pazh8x66dk
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDATobacco: Preventing at-risk teens from smoking is not only incredibly impactful to public health but beneficial to each and… https://t.co/TsgkLSXMw8
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDAOncology: Join us Nov. 27, 2018, for #FDAOncology's 2nd annual educational workshop for new cancer patient advocates, Partner… https://t.co/pAoymrra2L
SteveFDA (R-D.C.)
@SGottliebFDA
We are undertaking a comprehensive process to develop evidence based guidelines that can inform the more appropriate dispensing of opioids based on their indication for use; to reduce exposure and rationalize prescribing. https://t.co/4paAKeKfat
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDAMedia: FDA adds four tropical diseases to priority review voucher program to encourage drug development in areas of unmet… https://t.co/7YXf37ggRm
SteveFDA (R-D.C.)
@SGottliebFDA
Tropical diseases affect millions of people throughout the world. Today, #FDA added four tropical diseases to the priority review voucher (PRV) program to help stimulate drug development to prevent and treat infectious diseases. https://t.co/jr1ZZLUAqL